Rentschler Biopharma appoints new head of Milford facility
Photo | Courtesy of Rentschler Biopharma
Rentschler Biopharma celebrated the groundbreaking on its new Milford facility last year. The company appointed Mark Caswell as vice president, site head of the Milford facility.
A German biopharmaceutical manufacturing company has shifted its governance structure and hired an industry veteran as its new vice president and top executive at its Milford facility.
Rentschler Biopharma, which has locations in Milford as well as Laupheim, Germany, said Thursday it has hired Mark Caswell as vice president and site head, where he will manage all operations at the company’s U.S. facilities in Milford. Caswell’s responsibilities include overseeing the completion of the company’s new Rentschler Biopharma Manufacturing Center, which is being built next to its existing site.
Before joining Rentschler in July, Caswell worked for more than six years at Lonza Biologicals, where he was most recently head of operations at the company’s Portsmouth, N.H. site. He previously worked at Sanofi Genzyme in various ascending roles, including director of global engineering and technology.
With Caswell’s appointment, the company has made changes to its governance structure. Caswell will take over the responsibilities Martin Kessler performed as CEO of Rentschler Biopharma, and Kessler will now focus completely on the company’s transformation program.
Rentschler acquired its Milford site in 2019, which gave it a footprint in the U.S. Since then, the company has expanded capacity, and it broke ground on its new facility in 2021. It will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 single-use bioreactors.
WBJ Web Partners
Most Recent
Most Recent
0 Comments